Ferreira Tiago Bravo, Vaz Fernanda, Rodrigues Antonio, Donato Sofia
Hospital Egas Moniz, Ophthalmology, Rua da Junqueira 126, Lisboa, 1300, Portugal.
BMJ Case Rep. 2009;2009:bcr1020081110. doi: 10.1136/bcr.10.2008.1110. Epub 2009 May 21.
This report describes the first case of Aspergillus endophthalmitis after heart transplantation which was successfully treated with intravitreal voriconazole. A 62-year-old man receiving immunosuppressive agents after a heart transplant presented with pain, reduced visual acuity and redness of the left eye. The patient had been diagnosed with invasive pulmonary aspergillosis and was being treated with intravenous voriconazole. Endogenous endophthalmitis was diagnosed. Aspergillus fumigatus was isolated in a vitreous sample. After five intravitreal voriconazole injections (50 μg/0.1 ml), pars plana vitrectomy, intravenous and topical voriconazole treatment, there was no ocular inflammation and the visual acuity improved from counting fingers at 50 cm to 20/20. This case report shows that intravitreal voriconazole, in addition to topical and systemic treatment, was safe and very effective in treating Aspergillus endophthalmitis. More clinical studies are needed to determine the optimal treatment for this condition.
本报告描述了首例心脏移植术后曲霉菌性眼内炎病例,该病例经玻璃体内注射伏立康唑成功治愈。一名62岁男性在心脏移植后接受免疫抑制剂治疗,出现左眼疼痛、视力下降和眼红症状。该患者此前被诊断为侵袭性肺曲霉病,正在接受静脉注射伏立康唑治疗。诊断为内源性眼内炎。在玻璃体样本中分离出烟曲霉。经5次玻璃体内注射伏立康唑(50μg/0.1ml)、睫状体平坦部玻璃体切除术、静脉及局部应用伏立康唑治疗后,眼部炎症消失,视力从50cm处数指提高到20/20。本病例报告表明,除局部和全身治疗外,玻璃体内注射伏立康唑治疗曲霉菌性眼内炎安全且非常有效。需要更多临床研究来确定针对这种情况的最佳治疗方法。